Potential Role of Fluoroquinolones in Pediatric Infections

Keyphrases

• Fluoroquinolones 100%
• Pediatric Infections 100%
• Cartilage 40%
• United States 20%
• Clinical Trials 20%
• Antibiotics 20%
• Pediatric 20%
• Leukemia 20%
• Pseudomonas Aeruginosa (P. aeruginosa) 20%
• Serum Levels 20%
• Animal Species 20%
• Tissue Level 20%
• Europe 20%
• Methicillin-resistant Staphylococcus Aureus 20%
• Cystic Fibrosis 20%
• Clinical Experience 20%
• Infections in children 20%
• Meningitis 20%
• Pediatric Diseases 20%
• Antimicrobial 20%
• Oral Administration 20%
• Haemophilus Influenzae 20%
• Acute Pulmonary Infection 20%
• Resistant Bacteria 20%
• Minimum Inhibitory Concentration 20%
• Staphylococcal Infections 20%
• Spectrum of Activity 20%
• Multiple Resistance 20%
• Immunocompromised children 20%
• Therapeutic Failure 20%
• Failure Resistance 20%
• Methicillin Resistance 20%
• Joint Toxicity 20%
• Quinolone Derivatives 20%
• Chronic Pulmonary Infections 20%
• Nalidixic Acid 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Infection 100%
• Quinolone Derivative 100%
• Clinical Trial 16%
• Infectious Agent 16%
• Antibiotics 16%
• Pseudomonas aeruginosa 16%
• Antiinfective Agent 16%
• Methicillin-Resistant Staphylococcus Aureus 16%
• Lung Infection 16%
• Meningitis 16%
• Cystic Fibrosis 16%
• Haemophilus influenzae 16%
• Meticillin 16%
• Staphylococcal Infection 16%
• Nalidixic Acid 16%
• Diseases 16%
• Oral Administration 16%